{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-24-000014","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.121632+00:00","generated_at":"2026-06-04T22:22:45.599106+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Entrada Therapeutics FY2023 net loss $6.7M, cash $352M; DMD Phase 1 data on track","bullets":["Cash, equivalents and marketable securities $352.0M as of Dec 31, 2023, up from $188.7M; runway through Q2 2026.","Collaboration revenue $129.0M full year (Vertex deal); net loss narrowed to $6.7M from $94.6M in 2022.","Completed dosing first three cohorts of ENTR-601-44 Phase 1 for DMD; data readout H2 2024.","Regulatory applications expected Q4 2024 for global Phase 2 of ENTR-601-44 and ENTR-601-45.","Promoted Nathan Dowden to President & COO; appointed Kevin Healy (SVP Regulatory) and Marie Rosenfeld (SVP Clinical Ops)."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-24-000014","json":"https://secwatch.observer/filing/0001689375-24-000014.json","markdown":"https://secwatch.observer/filing/0001689375-24-000014.md","text":"https://secwatch.observer/filing/0001689375-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/0001689375-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/trda-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:22:45.599106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e2ed061071181a63322d8ac412380d597bfb92d","claim":"Entrada Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss was $6.7 million for the full year of 2023.","evidence_excerpt":"On March 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2023 and other corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/0001689375-24-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $6.7 million for the full year of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}